Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

European Medicines Agency Adopts Positive Opinion for Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Adults with Metastatic Squamous Non-Small Cell LFebruary 4, 2019 6:45 AM Pre-Open Stock Movers 02/01: (TTNP) (DECK) (SYMC) Higher; (CORT) (KLIC) (AMZN) Lower (more...)February 1, 2019 9:27 AM Merck (MRK) Tops Q4 EPS by 1c, Offers FY GuidanceFebruary 1, 2019 6:47 AM